###begin article-title 0
Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 649 658 646 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 894 903 890 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 352 355 <span type="species:ncbi:8790">Emu</span>
###xml 458 461 <span type="species:ncbi:8790">Emu</span>
###xml 521 524 <span type="species:ncbi:8790">Emu</span>
###xml 728 731 <span type="species:ncbi:8790">Emu</span>
###xml 977 980 <span type="species:ncbi:8790">Emu</span>
###xml 1129 1132 <span type="species:ncbi:8790">Emu</span>
Bright/ARID3A is a nuclear matrix-associated transcription factor that stimulates immunoglobulin heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu). Over-expression of Bright in cultured B cells was shown to correlate with DNase hypersensitivity of Emu. We report here further efforts to analyze Bright-mediated Emu enhancer activation within the physiological constraints of chromatin. A system was established in which VH promoter-driven in vitro transcription on chromatin- reconstituted templates was responsive to Emu. Bright assisted in blocking the general repression caused by nucleosome assembly but was incapable of stimulating transcription from prebound nucleosome arrays. In vitro transcriptional derepression by Bright was enhanced on templates in which Emu is flanked by MARs and was inhibited by competition with high affinity Bright binding (P2) sites. DNase hypersensitivity of chromatin-reconstituted Emu was increased when prepackaged with B cell nuclear extract supplemented with Bright. These results identify Bright as a contributor to accessibility of the IgH enhancer.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 144 145 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 149 156 148 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 307 308 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 309 310 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 483 484 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 485 486 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 638 640 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 797 798 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 77 80 <span type="species:ncbi:8790">Emu</span>
###xml 158 161 <span type="species:ncbi:8790">Emu</span>
###xml 408 411 <span type="species:ncbi:8790">Emu</span>
###xml 579 582 <span type="species:ncbi:8790">Emu</span>
Numerous studies have demonstrated the requirement of the intronic enhancer (Emu) in transcription of immunoglobulin heavy chains (reviewed in [1]). In vivo, Emu is required for successful B-cell development, and in its absence, completion of antigen receptor assembly through VDJ recombination is blocked [2,3]. Based on chromatin immunoprecipitation (ChIP) measurements of its histone modification status, Emu assumes an accessible chromatin configuration specifically in B cells [4-6]. Conventional transcription factors may seize upon this B cell-accessible state to bind to Emu for transactivation via VDJ-associated promoters (Fig. 1A). Transcriptional activators further exploit increasingly accessible chromatin structures to enhance their binding as B cells progress through development [7].
###end p 4
###begin p 5
###xml 89 93 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A,B</xref>
###xml 96 97 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 327 328 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 515 517 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 518 520 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 642 644 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 744 746 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 808 810 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 811 813 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 838 846 833 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 914 916 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1101 1103 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1316 1317 1310 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1318 1320 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1321 1323 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1357 1365 1351 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1591 1593 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1594 1596 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 4 7 <span type="species:ncbi:8790">Emu</span>
###xml 137 140 <span type="species:ncbi:8790">Emu</span>
###xml 359 362 <span type="species:ncbi:8790">Emu</span>
###xml 454 457 <span type="species:ncbi:8790">Emu</span>
###xml 663 666 <span type="species:ncbi:8790">Emu</span>
###xml 1133 1136 <span type="species:ncbi:8790">Emu</span>
###xml 1446 1449 <span type="species:ncbi:8790">Emu</span>
###xml 1574 1589 <span type="species:ncbi:10090">transgenic mice</span>
The Emu core is flanked on both sides by nuclear matrix associating regions (MARs) (Fig. 1A,B) [8]. As proposed for MARs in general, the Emu MARs are thought to anchor higher order chromatin into discrete looped domains and to attach them to the nuclear matrix - a site where proteins essential for transcription might reside [9]. While the importance of the Emu core is universally accepted, the role of their associated MARs remains controversial. The Emu MARs were initially implicated in locus down-regulation [10-12], an argument strengthened by the observation that the enhancer core alone will activate gene expression in non-B cells [12]. Conversely, the Emu MARs have been shown to stimulate IgH transcription in B cells (reviewed in [13]), perhaps by impacting chromatin structure of the enhancer [14-17]. For example, targeted in vivo deletion of both intronic MARs reduced IgH transcription 5-10 fold [17]. However, deletion of the endogenous MARs in a hybridoma cell line had modest effects, implying a redundant function for the MARs and the core enhancer in maintaining IgH expression [18]. Studies which examined the Emu MARs in VDJ rearrangement have had variable outcomes, largely depending on the method used to delete the MARs and whether the endogenous locus or a transgenic locus was examined [3,18-20]. A requirement for MAR function in vivo but not in cell lines was most convincingly demonstrated by the finding that the Emu MARs were necessary for generating long-range chromatin accessibility in ectopically integrated reporter gene constructs in transgenic mice [16,17].
###end p 5
###begin p 6
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 155 0 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematics of the immunoglobulin heavy chain (IgH) locus and of the templates and strategies used for chromatin reconstituted <italic>in vitro </italic>transcription assays</bold>
###xml 157 160 157 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 346 349 343 346 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 767 770 764 767 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C)</bold>
###xml 786 795 783 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1067 1070 1063 1066 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(D)</bold>
###xml 1111 1120 1107 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1187 1196 1183 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1200 1209 1196 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1338 1341 1334 1337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(E)</bold>
###xml 1378 1387 1374 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 162 165 <span type="species:ncbi:8790">Emu</span>
###xml 196 202 <span type="species:ncbi:10090">murine</span>
###xml 204 207 <span type="species:ncbi:10090">IgH</span>
###xml 324 327 <span type="species:ncbi:8790">Emu</span>
###xml 911 917 <span type="species:ncbi:10090">murine</span>
###xml 1018 1021 <span type="species:ncbi:8790">Emu</span>
Schematics of the immunoglobulin heavy chain (IgH) locus and of the templates and strategies used for chromatin reconstituted in vitro transcription assays. (A). Emu within the rearranged VDJ-Cmu murine (IgH) locus. Promoter, p; direction of transcription, rightward arrow; exons, open boxes; 5' and 3' MARs, hatched boxes; Emu core, filled box. (B). Detailed schematic of the enhancer sites indicating DNA binding sites and proteins that bind to them to activate (positive factors) or to repress (negative factors) transcription (reviewed in [1]). P1-P4 denote Bright-binding ''P sites'' within the 5' and 3' MARs; the strong P2 site of Bright is indicated by a filled circle. Hinf1 sites (H) operationally define the core region, and XbaI sites (X) flank the MARs. (C). Templates for in vitro chromatin assembly/transcription. VDJ and upstream region was derived from the rearranged VDJ expressed by the BCL1 murine leukemia cell line (37). Templates contain VDJ with no enhancer (P-only) or, ~2 kbp downstream, the Emu core with (+) or without the 5' and 3' MARs. (D). Probes and protected products used for in vitro transcription reactions and RNAse protection assays. Transcription in vitro and in vitro is initiated from two major start sites (indicated by arrows), resulting in protected products (shown below) of 55 and 43 bases. (E). Order of addition and strategy for in vitro transcription reactions. As detailed in the text, Step 1 conditions examine transcription following addition of factors (extract only, recombinant Bright, or Bright-supplemented extract) or buffer alone prior to chromatin assembly upon templates. Step 2 conditions measure transcription when factors are added after assembly of chromatin. Transcription is initiated by addition of nucleoside-triphosphates (NTPs).
###end p 6
###begin p 7
###xml 37 38 37 38 <underline xmlns:xlink="http://www.w3.org/1999/xlink">B</underline>
###xml 55 56 55 56 <underline xmlns:xlink="http://www.w3.org/1999/xlink">r</underline>
###xml 68 71 68 71 <underline xmlns:xlink="http://www.w3.org/1999/xlink">IgH</underline>
###xml 71 72 71 72 <underline xmlns:xlink="http://www.w3.org/1999/xlink">t</underline>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 214 216 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 352 354 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 355 357 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 581 583 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 752 757 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F1 </italic>
###xml 758 760 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 970 972 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 973 975 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 171 174 <span type="species:ncbi:8790">Emu</span>
###xml 209 212 <span type="species:ncbi:10090">IgH</span>
###xml 396 399 <span type="species:ncbi:10090">IgH</span>
Bright, a nuclear matrix-associated, B cell-restricted regulator of IgHtranscription, binds with differential affinity to four ATC-rich motifs (P1-P4, Fig. 1B) within the Emu MARs to activate transcription of IgH [21]. Bright is stage-specifically expressed in B lymphocytes, where it accumulates primarily within the cytoplasm and the nuclear matrix [22-24]. In addition to its participation in IgH transcription, a function for Bright in cell cycle regulation was suggested by the finding that a fraction of nuclear matrix-associated Bright fractionated into PML nuclear bodies [25]. Consistent with this notion, ectopic over-expression of Bright in embryonic fibroblasts leads to their immortalization via accumulation of Cyclin E and activation of E2F1 [26]. Potential relevance of these observations to B-cell malignancy is suggested by the finding that the sub-type of diffuse large B-cell lymphoma with the worst clinical prognosis has elevated levels of Bright [27,28].
###end p 7
###begin p 8
###xml 57 59 57 59 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AT</underline>
###xml 60 61 60 61 <underline xmlns:xlink="http://www.w3.org/1999/xlink">R</underline>
###xml 65 66 65 66 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 77 78 77 78 <underline xmlns:xlink="http://www.w3.org/1999/xlink">D</underline>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 631 633 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 634 636 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 755 757 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 43 49 <span type="species:ncbi:9606">humans</span>
###xml 160 165 <span type="species:ncbi:4932">yeast</span>
###xml 581 584 <span type="species:ncbi:8790">Emu</span>
###xml 745 748 <span type="species:ncbi:8790">Emu</span>
Bright is the founder of the 13-member (in humans) ARID (AT-Rich Interaction Domain) family [29]. Bright/ARID3A and several other ARID members (or their fly or yeast orthologues) have been implicated directly or indirectly in chromatin remodeling [30-35]. As often seen with remodeling proteins, Bright has strict contextual requirements for transactivation [21,30]. For example, Bright cannot transactivate via out-of-context, concatenated P binding sites, and transactivation is maximal on integrated substrates [21,30]. Bright binding to its highest affinity P2 site within the Emu 5' MAR induces severe (80-90)degrees bending [21,30]. Over-expression of Bright in a mature B cell line induced DNAse I hypersensitivity extending through both Emu MARs [30]. These results suggest that the enhancer assumes a more open chromatin configuration as a direct or indirect consequence of Bright.
###end p 8
###begin p 9
###xml 127 136 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 88 91 <span type="species:ncbi:8790">Emu</span>
###xml 217 220 <span type="species:ncbi:8790">Emu</span>
To address the issue directly, we have examined Bright transcriptional activation in an Emu-responsive chromatin-reconstituted in vitro system. Our results support a role for Bright, or a Bright complex which retains Emu MAR binding, in chromatin remodeling of the enhancer.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
Rationale and reaction order
###end title 11
###begin p 12
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 70 79 70 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
In vitro transcription on reassembled chromatin templates is the only in vitro system in which transcriptional enhancement over distances of 1-2 kb has been achieved (e.g., [36]). Activity requires that the template be packaged into chromatin and that the transcriptional regulatory factors be present before or during chromatin formation so that general repression caused by nucleosome assembly will be blocked.
###end p 12
###begin p 13
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 240 241 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 434 443 434 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 651 653 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 498 501 <span type="species:ncbi:8790">Emu</span>
###xml 514 517 <span type="species:ncbi:8790">Emu</span>
###xml 549 552 <span type="species:ncbi:8790">Emu</span>
The 3 template DNAs employed in this study are shown in Fig. 1C, and their construction is detailed in Methods and Materials. Transcription is driven from the promoter of the rearranged VDJ expressed by the BCL1 leukemia B cell line [37]. VHBCL1 extends ~270 bp upstream of the 5' most transcriptional initiation site and includes the conserved heptamer and octamer binding motifs [38] (Fig. 1D). VHBCL1 has been shown to have strong in vitro activity when assayed in nuclear extracts [39,40]. The Emu core alone (Emu) or flanked by 5' and 3' MARs (Emu+MARs) is positioned ~2 kb downstream (or ~400 bp upstream on the circular plasmid backbone) (Fig. 1C).
###end p 13
###begin p 14
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 336 347 336 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophlia </italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 548 549 548 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
Our experimental design is shown in Fig. 1E. There are two orders of addition. In the first, naked DNA templates are prebound with nuclear extract from B-cell lines, or with recombinant Bright, or with B-cell extracts supplemented with recombinant Bright (or with buffer) (Step 1). Chromatin is assembled using S-190 extracts from 4 hr Drosophlia embryos supplemented with core histones [41,42]. Following chromatin assembly (Step 2), packaged templates are assayed upon addition of nucleotide triphosphates for transcription initiated off of the VHBCL1 promoter by quantitative RNase protection. Chromatin alterations are measured by DNase I digestion and indirect end labeling. In the second order of addition, extracts or purified Bright are added following chromatin assemblies.
###end p 14
###begin p 15
The Step 1 condition will reveal direct effects on chromatin structure. In this scheme, extracts or purified Bright prebound to the naked DNA template before or during chromatin formation can derepress the general transcriptional repression of assembled nucleosomes. If an effect is seen at addition of extract or Bright at step 2, this would suggest that transcriptional activation requires binding to a pre-formed, reconstituted nucleosome array.
###end p 15
###begin title 16
###xml 25 28 <span type="species:ncbi:10090">IgH</span>
Assembly of chromatin on IgH templates
###end title 16
###begin p 17
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 221 222 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 547 556 546 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 195 198 <span type="species:ncbi:8790">Emu</span>
Chromatin assembly on the three templates described above was carried out as detailed in Materials and Methods. A kinetic analysis of micrococcal nuclease (MNase) digestion of assembly on VHBCL1-Emu+MARs is shown in Fig. 2. Assembly was complete in ~30 min, and in the absence of an ATP regenerating system (-ATP lanes), assembly was suppressed. Similar results were obtained for the other templates using this assay and for all templates using a DNA supercoiling assay (data not shown). We conclude that our nucleosomal arrays are sufficient for in vitro transcription.
###end p 17
###begin p 18
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vitro </italic>nucleosomal arrays assembled on the IgH enhancer</bold>
###xml 45 48 <span type="species:ncbi:10090">IgH</span>
###xml 163 166 <span type="species:ncbi:8790">Emu</span>
In vitro nucleosomal arrays assembled on the IgH enhancer. The rate and extent of the chromatin reconstitution reaction (detailed in Methods and Materials) on the Emu+MARs template (Fig. 1C) was monitored by formation of nucleosomes. Aliquots were removed at regular 2-240 min intervals, digested with MNase for 5 min, fractionated on a 1.5% agarose gel, and then stained with ethidium bromide. Outside lanes, naked DNA; -ATP lanes, no ATP regeneration system.
###end p 18
###begin title 19
###xml 19 28 19 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 84 87 <span type="species:ncbi:8790">Emu</span>
Transcription from in vitro assembled VH-promoter-driven templates is responsive to Emu
###end title 19
###begin p 20
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 353 355 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 369 371 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 397 406 395 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 461 462 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1035 1036 1033 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1102 1105 1100 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1460 1469 1451 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1667 1669 1658 1660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 67 70 <span type="species:ncbi:10090">IgH</span>
###xml 239 242 <span type="species:ncbi:8790">Emu</span>
###xml 246 249 <span type="species:ncbi:8790">Emu</span>
###xml 294 299 <span type="species:ncbi:9606">human</span>
###xml 429 432 <span type="species:ncbi:10090">IgH</span>
###xml 1149 1152 <span type="species:ncbi:8790">Emu</span>
###xml 1244 1247 <span type="species:ncbi:8790">Emu</span>
###xml 1354 1357 <span type="species:ncbi:8790">Emu</span>
###xml 1382 1385 <span type="species:ncbi:8790">Emu</span>
###xml 1389 1392 <span type="species:ncbi:8790">Emu</span>
###xml 1690 1693 <span type="species:ncbi:8790">Emu</span>
###xml 1724 1727 <span type="species:ncbi:10090">IgH</span>
Having succeeded in reconstituting regularly spaced nucleosomes on IgH template DNA, we tested whether the templates of Fig. 1C could direct transcription and, importantly, whether their activities were sensitive to the presence in cis of Emu or Emu+MARs. We prepared nuclear extracts from the human Burkitt lymphoma line, BJAB, shown previously by us [39] and others [43] to be highly active for in vitro transcription of naked IgH templates. As shown in Fig. 3, transcripts were correctly initiated from all templates in the absence (N lanes) or presence (D and R lanes) of chromatin as confirmed by their sizes relative to authentic BCL1 transcripts (lane 2). Transcription initiated from each template was repressed (R) when reconstituted with chromatin prior to addition of BJAB nuclear extract under Step 2 conditions (R lanes 5, 8, and 11). Importantly, transcription was derepressed (D) for all templates by pre-binding BJAB nuclear extract (D lanes 4, 7, and 10). Equal inputs, confirmed by anti-Bright Western blotting (Fig. 3, lower panel) allowed us to estimate the quantitative effects of cis-acting sequences. Importantly, we observed Emu enhancer-dependent stimulation in this system under Step 1 conditions (compare D lanes +/- Emu ; lanes 4 vs 7). The inclusion of 5' and 3' MARs reproducibly enhanced transcription levels achieved with Emu alone (compare D lanes, Emu vs Emu+MARs; lanes 7 vs 10). We conclude that our chromatin reconstituted in vitro transcription system is responsive to the enhancer and adequate to address the central question of the role of Bright. Furthermore, the data are consistent with the conclusions of Forrester et al. [16] in suggesting that Emu MARs positively contribute to IgH transcriptional activity through a chromatin-based mechanism.
###end p 20
###begin p 21
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 0 196 0 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vitro </italic>transcription from the V<sub>H</sub>BCL1 promoter is stimulated by the IgH enhancer core alone (E&#956;) or the enhancer and associated MARs (E&#956;+MARs) on templates reconstituted under Step 1 conditions</bold>
###xml 318 319 316 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 493 504 488 499 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</underline>
###xml 558 565 553 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 966 977 958 969 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</underline>
###xml 69 72 <span type="species:ncbi:10090">IgH</span>
###xml 94 97 <span type="species:ncbi:8790">Emu</span>
###xml 136 139 <span type="species:ncbi:8790">Emu</span>
###xml 356 359 <span type="species:ncbi:8790">Emu</span>
###xml 374 377 <span type="species:ncbi:8790">Emu</span>
###xml 406 409 <span type="species:ncbi:8790">Emu</span>
###xml 683 688 <span type="species:ncbi:4932">yeast</span>
In vitro transcription from the VHBCL1 promoter is stimulated by the IgH enhancer core alone (Emu) or the enhancer and associated MARs (Emu+MARs) on templates reconstituted under Step 1 conditions. Transcription reactions were carried out as described in Materials and Methods on ~50 ng templates in which either the VHBCL1 promoter alone (P-only), or the Emu core without (Emu) or with its flanking MARs (Emu+MARs), were positioned ~2 kbp 3'. Transcription was initiated by addition of NTPs. Upper panel: BCL1 transcripts, which initiate at two major sites in vivo, were detected as described in Fig. 1C by RNase protection following fractionation on denatured gels. Lane 1, ~2 mug yeast RNA; lane 2, ~2 mug total RNA from BCL1 leukemia cells; N, naked DNA; D, pre-binding with BJAB nuclear extract (~5 mug/reaction) prior to assembly of chromatin (Step 1 conditions of Fig. 1E); R, post-binding of BJAB extract following assembly of chromatin (Step 2 conditions). Lower panel: Corresponding western blot of SDS-PAGE-fractionated reactions (~15 mug/lane) to monitor and normalize Bright protein levels within input BJAB nuclear extract.
###end p 21
###begin title 22
Choice and production of endogenous and recombinant Bright
###end title 22
###begin p 23
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 228 233 <span type="species:ncbi:9606">human</span>
We reasoned that the abundance of endogenous Bright within a B cell nuclear extract would directly correlate with its transcriptional activity. As shown in the Western analysis of Fig. 4A, Bright levels varied broadly among the human B cell lines examined. We prepared standard nuclear extracts fractionated over heparin agarose from the relatively Bright-low (Namalwa, lane 8) and Bright-high (Nalm6, lane 4) cell lines.
###end p 23
###begin p 24
###xml 167 175 167 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 644 646 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 692 694 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 993 995 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1068 1076 1067 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1084 1086 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 167 174 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 596 599 <span type="species:ncbi:8790">Emu</span>
###xml 1068 1075 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Next, we sought to purify recombinant Bright to replace or to complement extracts for reaction Steps 1 and 2. Several methods to produce full-length Bright (1-601) in E. coli were attempted, but these attempts were unsuccessful in producing functional protein (data not shown). The material remained insoluble and could not be actively (as judged by EMSA; data not shown) renatured from inclusion bodies. However, we produced sufficient quantities of an N-terminally His-tagged truncation (residues 177-601). This same truncation was previously shown to be indistinguishable from wild-type as an Emu transactivator in transfected B cell lines [21]. As judged by SDS-PAGE chromatography (Fig. 4B, left panel), Bright (177-601) was purified to near homogeneity by a combination of affinity and ion exchange chromatography. The faster migrating species was confirmed by Western analysis (data not shown) as a Bright degradation product. This degradation was prevented/significantly reduced (Fig. 4B, left panel, lane 5) by transformation into a chaperone over-expressing E. coli strain [44].
###end p 24
###begin p 25
###xml 208 210 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 441 443 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 785 794 784 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 159 162 <span type="species:ncbi:8790">Emu</span>
Following purification, proteins were tested for DNA binding by EMSA. The ~50 kD Bright (177-601) or its ~20 kD (d177-601) degradation product bound to the 5' Emu MAR-containing P2 site with specificity (Fig 4B, right panel, lanes 5-7) but with apparent lower affinity than endogenous Bright-containing Nalm6 extract (although it was difficult to compare their concentrations quantitatively). Full-length Bright binds to MARs as a tetramer [21], and the C-terminus-proximal REKLES domain (retained in both full-length and 177-601 proteins) is necessary and sufficient for tetramerization (24). Accordingly, the sizes of the DNA-protein complexes were consistent with multimerization of Bright (177-601). We conclude that bacterially-expressed Bright (177-601) is sufficient for use in in vitro transcription experiments.
###end p 25
###begin p 26
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of endogenous and recombinant Bright</bold>
###xml 50 54 50 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 542 546 541 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 633 643 632 642 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</underline>
###xml 1193 1198 1188 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">groE </italic>
###xml 1202 1207 1197 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">groF </italic>
###xml 1235 1246 1230 1241 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</underline>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 182 188 <span type="species:ncbi:10090">murine</span>
###xml 494 500 <span type="species:ncbi:9986">rabbit</span>
Preparation of endogenous and recombinant Bright. (A) Bright expression in human B cell lines. Crude nuclear extracts were prepared from the indicated B cell lines (lanes 2-9), from murine embryonic fibroblasts (MEFs) (-, lane 9) or from MEFs transduced with retroviral HA-Bright (+, lane 1). Approximately 15 mug/lane were fractionated on SDS-PAGE, and proteins were identified by western blotting with either an anti-ubc9 mAb (loading control, lower panel) or an affinity purified polyclonal rabbit anti-Bright antibody [21] (upper panel). (B) Purification from bacteria and analyses of Lac-inducible, His-tagged Bright (177-601). Left panel: SDS-PAGE/silver stain assay for purification after each step. Affinity chromatography on Ni beads (Affinity, lane 2) was followed by DEAE biogel agarose chromatography (DEAE, lane3). DNA affinity chromatography employing a Sepharose-conjugated, high-affinity Bright binding P2 site trimer [66] produced high yield and purification (not shown). But we were incapable of preventing the protein (grown in DH5alpha) from degradation to ~20 kD (Affinity 2X, lane 4) unless the plasmid was transformed into K1309 [44], a strain over-producing chaperones groE and groF (Affinity 2X+Chap, lane 5). Right panel: Specificity of P2 site-containing MAR binding of Bright (177-601) as judged by EMSA/competition. Lane 1, nuclear (N) extract prepared from BJAB B cells; lane 3, HA-Bright prepared from retrovirally transduced MEF nuclear extract; lanes 5 and 6, Bright (177-601) purified from E coli (protein inputs correspond to lanes 5 and 4, respectively, of left panel); lanes 2, 4, and 7, competition (of the corresponding protein sources (indicated by identically colored boxes at top of lanes) with ~150-fold molar excess of a P2 site-containing duplexed oligonucleotide [66]. The endogenous NF-muNR negative regulator [12,66] which binds to the same P sites as Bright (Fig. 1B) is the slower mobility complex indicated in lane 3.
###end p 26
###begin title 27
###xml 18 27 18 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Bright stimulates in vitro transcription by relieving the inhibitory effect of chromatin
###end title 27
###begin p 28
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 325 334 325 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1008 1009 1005 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1025 1026 1022 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 351 354 <span type="species:ncbi:8790">Emu</span>
###xml 362 365 <span type="species:ncbi:8790">Emu</span>
###xml 708 711 <span type="species:ncbi:8790">Emu</span>
###xml 1119 1122 <span type="species:ncbi:8790">Emu</span>
Transcription reactions were carried out using the templates, Bright-rich and low-concentration extracts, and recombinant Bright (177-601) protein described above. We summarize all the data in Table 1 and key RNase protection results are presented in Fig. 5. Both nuclear extracts, but not Bright (177-601) alone, stimulated in vitro transcription of Emu and of Emu+MARs equivalently as naked DNA templates (eg, N lanes 1,2,9,10). These activities were repressed when the factors were added in Step 2 following chromatin-reconstitution on the templates (R lanes 3,4,11,12). Step 1 prebinding of all extracts derepressed (D lanes) both templates to some extent, although consistently stronger activity on the Emu+MARs template was observed for the Bright-rich Nalm6 extract (compare lanes 13 and 15). Recombinant Bright (177-601) alone was incapable of transactivating any of the templates as naked DNA; nor did addition of Bright (177-601) alone derepress chromatin assembled templates (data not shown; Fig. 5, lane 4; Table 1). However, its addition at Step 1 strongly complemented the ability of Namalwa to derepress Emu+MARs (compare lanes 7 and 8), while providing a more modest co-activation to Bright-rich Nalm6 (lane 15 vs. lane 16). The data indicate a direct role for Bright in alleviating the chromatin-mediated repression of the enhancer.
###end p 28
###begin p 29
###xml 11 20 11 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Summary of in vitro transcription results of Figures 4, 5 and data not shown.
###end p 29
###begin p 30
Abbreviations are provided in the legend to Fig. 3. Intensity estimates of RPAs are indicated as weak to absent (-) or as increasingly significant (+ to ++++) above the appropriate control for the particular reaction condition step.
###end p 30
###begin p 31
###xml 10 19 10 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 151 0 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Levels of <italic>in vitro </italic>transcription from chromatin assembled IgH enhancer templates correlate with levels of endogenous or recombinant-complemented Bright</bold>
###xml 543 554 540 551 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Upper panel</underline>
###xml 713 724 709 720 <underline xmlns:xlink="http://www.w3.org/1999/xlink">Lower panel</underline>
###xml 58 61 <span type="species:ncbi:10090">IgH</span>
###xml 205 208 <span type="species:ncbi:8790">Emu</span>
###xml 223 226 <span type="species:ncbi:8790">Emu</span>
###xml 251 254 <span type="species:ncbi:8790">Emu</span>
Levels of in vitro transcription from chromatin assembled IgH enhancer templates correlate with levels of endogenous or recombinant-complemented Bright. Transcription reactions and templates utilizing the Emu core without (Emu) or with flanking MARs (Emu+MARs) were measured by RNase protection as described in legends to Figs. 1, 3, and Materials and Methods. Transcription reactions were performed on N, naked DNA; R, reconstituted chromatin (Step 2 reaction order conditions); or D, prebound chromatin (Step 1 conditions). Protein sources: Upper panel (lanes 1-8): heparin agarose purified nuclear extracts prepared from Namalwa (5 mug/reaction) that contain low levels of endogenous Bright (Fig. 4A, lane 8); Lower panel (lanes 9-16): Nalm6 nuclear extract (5 mug/reaction) containing high levels of endogenous Bright (Fig. 4A, lane 4). Extracts were supplemented in the indicated lanes (+) with ~20 ng of purified Bright (177-601; Fig 4B, lane 5). Shown are phosphoimages of transcription reactions following protein removal and fractionation on 6% acrylamide/5 M urea gels.
###end p 31
###begin title 32
Enhancer derepression by Bright requires P site-specific MAR binding
###end title 32
###begin p 33
###xml 70 71 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 251 252 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 255 257 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 258 260 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 203 206 <span type="species:ncbi:8790">Emu</span>
To determine if the Bright (177-601) complementation observed in Fig. 5 required MAR binding, we titrated into Step 1 reactions duplex oligonucleotides corresponding to either a wild-type or mutated 5'- Emu MAR-containing P2 Bright binding site (Fig. 6) [21,30]. Specific, dose-dependent inhibition of transcription was observed for the wild-type, but not for the mutant P2 oligo. Although there are other interpretations, the simplest is that binding of Bright to its MAR-containing P2 site was specifically competed by excess P2 oligo.
###end p 33
###begin p 34
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Competition of Bright-complemented <italic>in vitro </italic>transcription by a high affinity Bright-binding P2 site</bold>
###xml 128 137 128 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 476 485 475 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 158 161 <span type="species:ncbi:8790">Emu</span>
Competition of Bright-complemented in vitro transcription by a high affinity Bright-binding P2 site. Prior to NTP initiation of in vitro transcription on the Emu+MARs template, either no oligonucleotide (lanes 1,2), or increasing concentrations of a duplexed wild-type P2 oligo (lanes 5,6) or a duplexed mutant (mut) P2 oligo (substituted in 5 core positions to eliminate Bright binding) (lanes 7,8) were added to the reaction prior to chromatin assembly (Step 1 conditions). In vitro generated transcripts were measured by RNase protection and compared to total RNA isolated from BCL1 leukemia cells (~0.5 mug; lane 9).
###end p 34
###begin title 35
Bright levels correlate with increased enhancer accessibility
###end title 35
###begin p 36
###xml 136 145 136 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 299 300 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 148 151 <span type="species:ncbi:8790">Emu</span>
DNase I hypersensitivity sites coincide with nucleosome-free regions in chromatin. We analyzed the accessibility of chromatin assembled in vitro on Emu+MARs to factors present in Namalwa nuclear extract in the absence or presence of Bright (177-601) under Step 1 conditions by DNase digestion (Fig. 7). Preferred sites of DNase I cleavage were examined with respect to a downstream BglI site by using a proximal probe (detailed in Materials and Methods). While the effect was modest, Bright (177-601)-complemented Namalwa extract rendered a consistently increased and extended hypersensitivity across the enhancer (compare lanes 3 among the panels). These results suggest that the enhancer assumes a more open chromatin configuration as a direct consequence of Bright.
###end p 36
###begin p 37
###xml 0 106 0 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Complementation of Namalwa with Bright enhances DNase hypersensitivity of chromatin-assembled IgH enhancer</bold>
###xml 118 127 118 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 94 97 <span type="species:ncbi:10090">IgH</span>
###xml 142 145 <span type="species:ncbi:8790">Emu</span>
###xml 186 189 <span type="species:ncbi:8790">Emu</span>
Complementation of Namalwa with Bright enhances DNase hypersensitivity of chromatin-assembled IgH enhancer. Following in vitro transcription, Emu+MARs DNA template alone (left panel) or Emu+MARs reconstituted under Step 1 conditions with either Namalwa nuclear extract alone (middle panel) or Namalwa complemented with Bright (177-601; right panel) were digested with 0, 1.0, 2.0 or 3.0 mug/ml DNase I (lanes 1-4 in each panel). DNA was purified, cut with Bgl II and analyzed by Southern blotting following hybridization with a downstream (XbaI-EcoRI) probe as described in Materials and Methods. Middle and right autoradiographs were exposed ~2.5 times longer so as to better visualize hypersensitive fragments (horizontal bars).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 106 109 <span type="species:ncbi:10090">IgH</span>
Numerous ubiquitous and B cell-specific transcription factors have been identified that transactivate the IgH enhancer (Fig. 1B; reviewed in [1]). Functional analyses underlying most characterizations have relied on transient reporter assays and have ignored to a large extent the physiological role of chromatin. Chromatin imposes an obligatory negative constraint upon enhancer accessibility. Thus, while conclusions derived from reporter approaches are valid in the context of accessible regulatory elements, they do not address many basic mechanisms of enhancer activation.
###end p 39
###begin p 40
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 301 303 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 304 306 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 487 489 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 492 494 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 495 497 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 544 553 541 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 629 631 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 781 783 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 786 788 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 789 791 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 223 226 <span type="species:ncbi:8790">Emu</span>
###xml 398 401 <span type="species:ncbi:8790">Emu</span>
###xml 571 574 <span type="species:ncbi:8790">Emu</span>
###xml 665 668 <span type="species:ncbi:8790">Emu</span>
The concept of locus accessibility is at the heart of antigen receptor VDJ and class switch recombination (reviewed in [45]). However, few bonafide accessibility factors have been identified. Perhaps the best characterized Emu accessibility factor is the ETS transcription factor family member, PU.1 [46,47]. PU.1 functions through the interaction with another ETS protein, Ets-1, to transactivate Emu and to stimulate enhancer accessibility in cultured cells via muB site binding (Fig. 1B) [48,49]. Importantly, PU.1 was observed to stimulate in vitro transcription and Emu accessibility from chromatin reconstituted templates [50]. In contrast, another essential Emu-binding transactivator, E47, appears to function indirectly by weak binding to accessible muE5/muE2 sites (Fig. 1B) [51,52].
###end p 40
###begin p 41
###xml 136 138 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 291 293 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 294 296 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 383 392 382 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 403 404 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 661 670 658 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 760 769 757 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 131 134 <span type="species:ncbi:8790">Emu</span>
###xml 449 452 <span type="species:ncbi:8790">Emu</span>
###xml 601 604 <span type="species:ncbi:8790">Emu</span>
###xml 890 893 <span type="species:ncbi:8790">Emu</span>
###xml 953 956 <span type="species:ncbi:8790">Emu</span>
We previously showed that Bright/ARID3A, when over-expressed in cultured WEHI 231 B cells, facilitated DNase I hypersensitivity of Emu [30]. Four other members of the 13 member ARID family (including SWI1/p270 of SWI/SNF) have been directly or indirectly implicated in chromatin remodeling [31-35]. Prompted by these observations, we established a system in which transcription from in vitro assembled VH-promoter-driven templates was responsive to Emu. We found that Bright could complement other B cell-derived factors to derepress the inhibitory effects of chromatin assembled on the enhancer. The Emu flanking MARs were required for maximal Bright-mediated in vitro transactivation. We demonstrated that the DNase I hypersensitivity of chromatin assembled in vitro on the enhancer was increased by Bright. These data indicate a direct role for Bright and further support a role for the Emu MARs in facilitating a fully accessible chromatin state of Emu.
###end p 41
###begin p 42
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 475 484 474 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 555 564 554 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 694 696 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 859 861 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 931 933 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 135 138 <span type="species:ncbi:8790">Emu</span>
###xml 1041 1044 <span type="species:ncbi:8790">Emu</span>
###xml 1336 1339 <span type="species:ncbi:8790">Emu</span>
Our previous analysis [30] and unpublished MNase digestion experiments on isolated B cell nuclei suggested that Bright may function by Emu nucleosomal disruption. The simplest mechanism to explain this effect would require that Bright reach the enhancer in the context of heterochromatin. However, the results reported here showed that Bright could alleviate chromatin-mediated repression only if it was delivered prior to chromatin assembly. That is, Bright cannot activate in vitro transcription by binding to a preformed nucleosome array. In contrast, in vitro assembled chromatin footprinting experiments revealed that PU.1 is capable of binding muB in the repressive context of chromatin [50]. The authors speculated that PU.1 might provide a platform for assembly of a "targesome", a protein complex required for a fully accessible chromatin structure [53]. Bright might participate in such a complex. However, as with PU.1 [50], our competition experiments indicated that Bright required an intact DNA binding site to mediate maximal Emu chromatin accessibility. This suggests that Bright is recruited independently and perhaps subsequently to PU.1, through direct binding to its P site(s). Both PU.1 and Bright might function to clear out nucleosomes otherwise positioned over critical cis-acting regulatory elements within the Emu core to provide accessibility to conventional DNA-binding transactivators.
###end p 42
###begin p 43
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 764 765 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 766 768 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 769 771 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 772 774 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 775 777 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 778 780 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 978 979 975 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1083 1085 1080 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1094 1095 1091 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1122 1124 1119 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1687 1689 1683 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 243 246 <span type="species:ncbi:8790">Emu</span>
###xml 651 654 <span type="species:ncbi:8790">Emu</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
###xml 854 857 <span type="species:ncbi:8790">Emu</span>
###xml 967 970 <span type="species:ncbi:10090">IgH</span>
###xml 1135 1139 <span type="species:ncbi:10090">mice</span>
###xml 1211 1215 <span type="species:ncbi:10090">mice</span>
###xml 1219 1223 <span type="species:ncbi:10090">mice</span>
###xml 1250 1253 <span type="species:ncbi:8790">Emu</span>
Regulation of chromatin structure by conventional protein-DNA interactions is generally considered to act only proximal to the DNA binding site [54,55]. MARs might offer an exception to this case. Forrester et al [16,56] demonstrated that the Emu MARs were required to obtain normal transcription initiation rates and to produce extended DNase I hypersensitivity across a VDJ-associated promoter over 2 kbp away. The mechanism underlying such distal accessibility induction is unknown, but it seems reasonable to speculate that a MAR-binding accessibility factor might contribute. As mentioned in the Background section, the contradictory evidence on Emu MAR function rests to a large extent on whether the endogenous locus or a transgenic locus was investigated [3,18-20,34-36,57]. For example, studies using chimeric mice with targeted deletion of the Emu MARs reported that these elements were dispensable for VDJ recombination and transcription of the endogenous IgH locus [3]. However, while the endogenous and MAR-deleted alleles were expressed at similar levels in splenic IgM+ B cells [3], the total numbers of IgM+ B cells in mice with a MAR deletion were less than half of those observed in wild-type mice or mice with deletion of only the Emu core. This suggests that deletions of the MAR elements may result in defects in B-cell development that have yet to be fully appreciated. The requirement for MAR function in transgenic animals, but not in cell lines or animals created from blastocyst fusions, is consistent with a MAR function in chromatin remodeling during early development or passage through the germline. This is consistent with the results of Forrester et al. [16] and those presented here.
###end p 43
###begin p 44
###xml 60 62 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
###xml 73 75 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 76 78 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 125 126 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 191 193 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 364 365 363 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 425 427 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 428 430 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 451 453 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
###xml 545 547 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 716 718 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 733 741 730 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 783 784 780 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1039 1041 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1096 1097 1092 1093 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 1220 1222 1216 1218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1223 1225 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 15 18 <span type="species:ncbi:8790">Emu</span>
###xml 20 23 <span type="species:ncbi:10090">IgH</span>
###xml 420 423 <span type="species:ncbi:8790">Emu</span>
###xml 457 460 <span type="species:ncbi:8790">Emu</span>
###xml 807 810 <span type="species:ncbi:8790">Emu</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
###xml 1331 1334 <span type="species:ncbi:10090">IgH</span>
###xml 1410 1413 <span type="species:ncbi:8790">Emu</span>
In addition to Emu, IgH-associated MARs often reside 5' of VH promoters [58-60]. A MAR upstream of the S107 variable region VH1 promoter was shown to contain specific Bright-binding P sites [59]. Indeed, Webb and colleagues have convincingly demonstrated that Bright can associate with both Bruton's tyrosine kinase and TFII-I to activate transcription of a S107 VH1 reporter through this proximal MAR in the absence of Emu [61,62]. The existence of VH and Emu-associated MARs and the ability of Bright to form multimeric MAR binding complexes [21] offers the possibility of looping enhancers and promoters into close proximity to stimulate transcription through nuclear matrix attachment-mediated domain formation [23]. Whether the in vivo mechanisms underlying promoter-proximal (VH) and promoter-distal (Emu) MAR-mediated transactivation by Bright are the same and can be accommodated by the looping model remain to be tested. In this context, we note that Bright levels in adult mice spike distinctly in large preB and mature B cells [22]. At the latter stage, maximal Bright expression and VH1 DNA binding are induced by mitogens and cytokines (e.g., LPS, IL-5, CD40L) that drive B lymphocytes into the cell cycle [21,22]. Perhaps Bright might utilize quite different transactivation options and/or function through different IgH MAR-associated binding sites under circumstances in which accessibility of Emu has already been established.
###end p 44
###begin p 45
###xml 231 235 231 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">V12 </sup>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 90 93 <span type="species:ncbi:10090">IgH</span>
Finally, we suggest that Bright may contribute to chromatin remodeling at loci other than IgH. Bright was shown to rescue primary fibroblasts from natural replicative senescence or from premature senescence induced by oncogenic RASV12 [26]. As with several other ARID factors [31,63], Bright binds retinoblastoma protein (Rb) (C. Schmidt and PWT, unpublished results), leading to the possibility that this tumour suppressor pathway is inactivated during senescence rescue. This hypothesis is consistent with the observation that Bright over-expression in MEFs activates E2F1 and Cyclin E1 [26]. Dean and colleagues [64] have provided a chromatin-based explanation for Rb/E2F transcriptional regulation which could accommodate a contributor with the properties of Bright.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 42 51 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 99 102 <span type="species:ncbi:10090">IgH</span>
We established a chromatin-reconstituted, in vitro transcription system which is responsive to the IgH enhancer. Our results support the conclusion that Bright contributes to enhancer function by increasing its accessibility through matrix attachment site binding.
###end p 47
###begin title 48
Materials and methods
###end title 48
###begin title 49
Constructs, probes and oligonucleotides
###end title 49
###begin p 50
###xml 26 35 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 360 361 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 537 538 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 545 546 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 694 695 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 710 711 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 954 963 950 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1108 1113 1104 1109 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ATTAA</underline>
###xml 1320 1322 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 367 370 <span type="species:ncbi:8790">Emu</span>
###xml 404 407 <span type="species:ncbi:8790">Emu</span>
###xml 551 554 <span type="species:ncbi:8790">Emu</span>
###xml 589 592 <span type="species:ncbi:8790">Emu</span>
###xml 1214 1217 <span type="species:ncbi:8790">Emu</span>
The template plasmids for in vitro transcription were constructed by cloning the 593 bp BamH1-XbaI fragment that spans the rearranged VDJ expressed by the BCL1 leukemia cell line [37] into pUC19. This fragment (VHBCL1) contains ~270 bp upstream of the 5' most transcriptional initiation site, including the conserved heptamer and octamer binding motifs [38]. VHBCL1- Emu was constructed by inserting the Emu enhancer core, as a 220 bp HinfI fragment, ~2 kbp downstream in transcriptional sense (~400 bp upstream on circular plasmid) of VHBCL1. VHBCL1-Emu+MARs was constructed by inserting Emu along with its flanking 5' and 3'MARs as a 911 bp Xba I fragment into the same location relative to VHBCL1. For the VHBCL1 antisense RNase protection probe, a 322 bp BamH1-NruI fragment containing ~55 bp downstream from the major initiation of transcription site was cloned into pGEM4 to generate pBCL1-5'. The plasmid was linearized with HinfI and transcribed in vitro by sp6 polymerase (Promega) to generate a 95 b RNA probe. Oligonucleotides corresponding to the + and - strands of wild-type (5'-CTTTTAACAATAATAAATTAAGTTTAAAATATTTTT-3') or mutated (underlined bases changed to TAATT) P2 Bright binding site within the Emu 5' MAR were synthesized, annealed, and the resulting duplex was gel purified as previously described [21].
###end p 50
###begin title 51
Cells
###end title 51
###begin p 52
###xml 191 199 191 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">groE </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">groF </italic>
###xml 421 424 421 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-1 </sup>
###xml 9 15 <span type="species:ncbi:10090">murine</span>
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 134 138 <span type="species:ncbi:9913">calf</span>
###xml 191 203 <span type="species:ncbi:511693">E. coli BL21</span>
The BCL1 murine leukemia, and human Burkitt's lymphomas (BJAB, Nalm6 and Namalwa) were maintained in RPMI supplemented with 10% fetal calf serum. For protein purification, we employed either E. coli BL21 Star (Invitrogen) or E coli K1309 [44], a strain overproducing chaperones groE and groF kindly provided by Dr. G. Georgiou (UT Austin, Dept. of Chem. Engineering). Induction of the chaperones was induced with 10 ng/ml-1 tetracycline at the beginning of the incubation in LB or M9 media.
###end p 52
###begin title 53
RNase protection
###end title 53
###begin p 54
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Labeling, purification, and denaturating gel analysis of the pBCL1-5' riboprobe were carried out as previously described [39]. After hybridization at 60degreesC overnight, unduplexed probe was digested with 40 ug RNase A (Sigma)/ml and 2500 U RNase T1 (BRL) for 1 hr at 37degreesC. Protected RNA fragments were separated on 6% acrylamide gels containing 8 M urea, and autoradiography was carried out for 24-96 hr.
###end p 54
###begin title 55
Protein manipulations
###end title 55
###begin p 56
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Nuclear extracts were prepared by the method of Dignam et al. [65] with minor modifications as described by Johnson et al. [39] to achieve final protein concentrations of 8-10 mg/ml.
###end p 56
###begin p 57
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 547 548 547 548 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
An N-terminal 6X-histidine-tagged Bright truncation (amino acids 177-601) was constructed as previously described [21], cloned into the pET30a+ expression vector (Novagen), and its expression induced with IPTG 30 min after chaperone induction (see above). Harvested cells were disrupted by sonication, and total cell lysates were analyzed on 12% SDS-PAGE (prior to or as a monitor of purification) with SilverStain (Invitrogen). Following elimination of cell debris by centrifugation, supernatants were purified by affinity chromatography over Ni2+-NTA agarose SuperFlow according to the manufacturer's instructions (Novagen and Qiagen). Further purification was carried out by DEAE Bio-Gel agarose chromatography as instructed by the vender (Pharmacia Fine Chemicals). The Bright-containing fraction was subjected to DNA affinity chromatography employing a Sepharose 6B-conjugated, high affinity Bright binding P2 site trimer (synthesis and elution conditions as described [66]). The final yield of purified Bright (177-601) was 8-20 mug from 2 l of M9 or LB media, respectively.
###end p 57
###begin p 58
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 258 262 <span type="species:ncbi:9925">goat</span>
###xml 268 274 <span type="species:ncbi:9986">rabbit</span>
Western analysis was performed according to Kim and Tucker [24]. Proteins were separated by 9% SDS-PAGE and transferred to Protran nitrocellulose membranes (Perkin Elmer). The membranes were incubated with anti-Bright polyclonal [21] and then developed with goat anti-rabbit IgG peroxidase-conjugated secondary (Amersham). Bands were visualized with ECL Western Blotting Detection Reagents (Amersham).
###end p 58
###begin title 59
Electrophoretic mobility shift assays (EMSA)
###end title 59
###begin p 60
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 289 291 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 269 272 <span type="species:ncbi:8790">Emu</span>
In vitro DNA binding and antibody supershift reactions were performed as previously described [21,66]. Briefly, either ~2 mug of nuclear extract or ~20 ng of purified Bright (177-601) was incubated with ~80,000 cpm of 5' end-labeled and gel-purified Bright-specific 5' Emu MAR probe (Fig. 1B). Samples were incubated for 20 min at room temperature and then resolved on 4% polyacrylamide gels.
###end p 60
###begin title 61
###xml 29 38 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Chromatin reconstitution and in vitro transcription
###end title 61
###begin p 62
###xml 66 77 66 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 132 143 132 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 571 572 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 651 653 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
Chromatin was assembled onto circular plasmid DNA templates using Drosophila core histones and S-190 assembly extract, derived from Drosophila embryos as previously described [41,42]. Briefly, template DNA (~500 ng), core histones (~400 ng), S-190 (~3.0 mug), 3 mM ATP plus an ATP regenerating system (30 mM phosphocreatine and 1 mug phosphocreatine kinase/ml) were incubated in 60 mM KCl. To monitor assembly, aliquots (~100 ng DNA) were removed at regular 2-240 min intervals, and then digested with micrococcal nuclease (MNase) (0.4 units/ml) for 5 min in a 30 mM CaCl2-containing, 10 mM Hepes (pH 7.5) buffer supplemented as previously described [42]. Reactions were deproteinized by protein K digestion, extracted with phenol/chloroform, ethanol precipitated, fractionated on a 1.5% agarose gel, and then visualized by ethidium bromide staining. Optimal assembly was achieved at ~1:.7 ratio of core histones: DNA.
###end p 62
###begin p 63
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 110 111 110 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 124 125 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 116 119 <span type="species:ncbi:8790">Emu</span>
###xml 130 133 <span type="species:ncbi:8790">Emu</span>
In vitro transcription was carried out as described [41,42] on ~50 ng naked or chromatin reassembled VHBCL1, VHBCL1-Emu or VHBCL1-Emu+MARs templates. Transcription was initiated by addition of 10 mM nucleoside triphosphates (NTPs). Complementation experiments were carried out by addition of B cell nuclear extracts (~5 mug/reaction) and/or purified Bright (177-601) (~20 ng/reaction). Variable orders of reaction were described in Results.
###end p 63
###begin title 64
Chromatin accessibility measurements
###end title 64
###begin p 65
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 358 361 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
###xml 522 527 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vacuo</italic>
###xml 783 786 781 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xba</italic>
###xml 788 791 786 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Eco</italic>
###xml 851 853 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 897 899 894 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9 </sup>
###xml 917 919 913 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 834 837 <span type="species:ncbi:8790">Emu</span>
DNase I digestion analysis of reconstituted chromatin templates was performed as described [30]. Aliquots (~100 ng DNA) were digested with DNase I (Worthington; 75 mug/ml) for various times at room temperature, purified by proteinase K digestion, phenol/chloroform/isoamyl alcohol (25:24:1) extraction and ethanol precipitation. Digests were restricted with BglII, fractionated on a 1.4% agarose gel containing 40 mM Tris acetate and 1 mM EDTA. The DNA was blotted overnight (Bio-Rad Zeta probe), neutralized, baked under vacuo, and then prehybridized for 2 hr overnight in 0.3 M NaCl, 15 mM sodium phosphate (pH 7.0), 1.5 mM EDTA, 0.5% BLOTTO dried milk powder, 1% SDS, and 500 mug/ml sonicated herring testis DNA. The blot was hybridized overnight in the same buffer to an ~300 bp XbaI-EcoRI restriction fragment (downstream to the Emu 3' MAR; Fig. 1B) radiolabeled to a specific activity of ~109 cpm/mug (~2.5 x 107 cpm) with a DNA labeling kit (Ambion). The sizes of hypersensitive fragments were estimated from linear fit of log DNA size vs mobility relative to DNA standards.
###end p 65
###begin title 66
Competing interests
###end title 66
###begin p 67
The author(s) declare that they have no competing interests.
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
DL, GCI, RTZ and JB performed in vitro transcription experiments, prepared and analyzed data, prepared figures and contributed to manuscript drafts. JK carried out protein purifications. PT directed the project, finalized the manuscript and procured funds to support the work.
###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
We thank Chhaya Das and Maya Ghosh for excellent technical assistance. We are grateful to Dr. James Kadonga for helpful discussions and generous sharing of reagents. We thank Dr. Daniel Peeper for Bright retroviral transduced fibroblasts, Paul Das for help with preparation of the manuscript, and members of our laboratory for critical comments. The work was supported by NIH grants 1F32CA110624-01A1 (GCI) and CA31534 (PWT) and the Marie Betzner Morrow endowment to PWT.
###end p 71
###begin article-title 72
Regulation of immunoglobulin mu heavy chain gene rearrangements
###end article-title 72
###begin article-title 73
###xml 15 18 <span type="species:ncbi:10090">IgH</span>
Elucidation of IgH intronic enhancer functions via germ-line deletion
###end article-title 73
###begin article-title 74
Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions
###end article-title 74
###begin article-title 75
Stepwise activation of the immunoglobulin mu heavy chain gene locus for recombination
###end article-title 75
###begin article-title 76
HMGA1 co-activates transcription in B cells through indirect association with DNA
###end article-title 76
###begin article-title 77
Antigen receptor loci poised for V(D)J rearrangement are broadly associated with BRG1 and flanked by peaks of histone H3 dimethylated at lysine 4
###end article-title 77
###begin article-title 78
The Ig kappa 3' enhancer is activated by gradients of chromatin accessibility and protein association
###end article-title 78
###begin article-title 79
The enhancer of the immunoglobulin heavy chain locus is flanked by presumptive chromosomal loop anchorage elements
###end article-title 79
###begin article-title 80
MARs of antigen receptor and co-receptor genes
###end article-title 80
###begin article-title 81
###xml 59 62 <span type="species:ncbi:10090">IgH</span>
Nuclear matrix attachment occurs in several regions of the IgH locus
###end article-title 81
###begin article-title 82
Negative regulation contributes to tissue specificity of the immunoglobulin heavy-chain enhancer
###end article-title 82
###begin article-title 83
A developmental-specific factor binds to suppressor sites flanking the immunoglobulin heavy-chain enhancer
###end article-title 83
###begin article-title 84
Matrix attachment region-dependent function of the immunoglobulin mu enhancer involves histone acetylation at a distance without changes in enhancer occupancy
###end article-title 84
###begin article-title 85
Nuclear matrix attachment regions confer long-range function upon the immunoglobulin mu enhancer
###end article-title 85
###begin article-title 86
The immunoglobulin mu enhancer core establishes local factor access in nuclear chromatin independent of transcriptional stimulation
###end article-title 86
###begin article-title 87
Dependence of enhancer-mediated transcription of the immunoglobulin mu gene on nuclear matrix attachment regions
###end article-title 87
###begin article-title 88
Extension of chromatin accessibility by nuclear matrix attachment regions
###end article-title 88
###begin article-title 89
Role of the intronic elements in the endogenous immunoglobulin heavy chain locus - Either the matrix attachment regions or the core enhancer is sufficient to maintain expression
###end article-title 89
###begin article-title 90
V(D)J recombination in B cells is impaired but not blocked by targeted deletion of the immunoglobulin heavy chain intron enhancer
###end article-title 90
###begin article-title 91
The V(D)J recombinational and transcriptional activities of the immunoglobulin heavy-chain intronic enhancer can be mediated through distinct protein-binding sites in a transgenic substrate
###end article-title 91
###begin article-title 92
The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family
###end article-title 92
###begin article-title 93
Expression of bright at two distinct stages of B lymphocyte development
###end article-title 93
###begin article-title 94
Differential regulation of immunoglobulin gene transcription via nuclear matrix-associated regions
###end article-title 94
###begin article-title 95
A regulated nucleocytoplasmic shuttle contributes to Bright's function as a transcriptional activator of immunoglobulin genes
###end article-title 95
###begin article-title 96
Regulation of MAR-Dependent, Lymphocyte-Restricted Transcription through Differential Localization within PML Nuclear Bodies
###end article-title 96
###begin article-title 97
Functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence
###end article-title 97
###begin article-title 98
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
###end article-title 98
###begin article-title 99
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
###end article-title 99
###begin article-title 100
Nomenclature of the ARID family of DNA-binding proteins
###end article-title 100
###begin article-title 101
Transcriptional Activation by a MAR Binding Protein: Contextual Requirements for the Function of Bright
###end article-title 101
###begin article-title 102
RBPI recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest
###end article-title 102
###begin article-title 103
RBPI recruits both histone deacetylase-dependent and independent repression activities to reinoblastoma family proteins
###end article-title 103
###begin article-title 104
JmjC: cupin metalloenzyme-like domains in jumonji, hairless and phospholipase A2beta
###end article-title 104
###begin article-title 105
A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer
###end article-title 105
###begin article-title 106
P300/CREB binding protein - related protein p270 is a component of mammalian SWI/SNF complexes
###end article-title 106
###begin article-title 107
Regulated expression of the beta-globin gene locus in synthetic nuclei
###end article-title 107
###begin article-title 108
Simultaneous Expression of Cmu and Cd Genes In a Cloned B Cell Line
###end article-title 108
###begin article-title 109
###xml 72 74 72 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
Interaction of Cell-Type-Specific Nuclear Proteins with Immunoglobulin VH Promoter-Region Sequences
###end article-title 109
###begin article-title 110
The ubiquitous octamer-binding protein(s) is sufficient for transcription of immunoglobulin genes
###end article-title 110
###begin article-title 111
###xml 49 51 49 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H </sub>
Differential transcription efficiency of two Ig VH promoters in vitro
###end article-title 111
###begin article-title 112
###xml 73 96 <span type="species:ncbi:7227">Drosophila melanogaster</span>
ATP-facilitated chromain assembly with a nucleoplasmin-like protein from Drosophila melanogaster
###end article-title 112
###begin article-title 113
Octamer binding proteins from B or Hela cells stimulate transcription of the immunoglobulin heavy-chain promoter in vitro
###end article-title 113
###begin article-title 114
###xml 114 119 <span type="species:ncbi:9606">human</span>
Using codon optimization, chaperone co-expression, and rational mutagenesis for production and NMR assignments of human eIF2a
###end article-title 114
###begin article-title 115
Accessibility control of recombination at the immunoglobulin locus
###end article-title 115
###begin article-title 116
PU.1 as a chromatin accessibility factor for immunoglobulin genes
###end article-title 116
###begin article-title 117
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
###end article-title 117
###begin article-title 118
Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins
###end article-title 118
###begin article-title 119
Combinatorial determinants of tissue-specific transcription in B cells and macrophages
###end article-title 119
###begin article-title 120
ETS protein-dependent accessibility changes at the immunoglobulin mu heavy chain enhancer
###end article-title 120
###begin article-title 121
E47 activates the Ig-heavy chain and TdT loci in non-B cells
###end article-title 121
###begin article-title 122
Identification of E2A target genes in B lymphocyte development by using a gene tagging-based chromatin immunoprecipitation system
###end article-title 122
###begin article-title 123
Mechanisms of mu enhancer regulation in B lymphocytes
###end article-title 123
###begin article-title 124
Mapping DNA interaction sites of chromosomal proteins using immunoprecipitation and polymerase chain reaction
###end article-title 124
###begin article-title 125
Targeted recruitment of the Sin3-Rpd3 histone deacetylase complex generates a highly localized domain of repressed chromatin in vivo
###end article-title 125
###begin article-title 126
Nuclear matrix attachment regions antagonize methylation-dependent repression of long-range enhancer-promoter interactions
###end article-title 126
###begin article-title 127
Expression of the (recombinant) endogenous immunoglobulin heavy-chain locus requires the intronic matrix attachment regions
###end article-title 127
###begin article-title 128
Novel protein-DNA interactions associated with increased immunoglobulin transcription in response to antigen plus interleukin-5
###end article-title 128
###begin article-title 129
Identification of a matrix-associated region 5' of an immunoglobulin heavy chain variable region gene
###end article-title 129
###begin article-title 130
###xml 118 121 <span type="species:ncbi:10090">IgH</span>
High frequency of matrix attachment regions and cut-like protein x/CCAAT-displacement protein and B cell regulator of IgH transcription binding sites flanking Ig V region genes
###end article-title 130
###begin article-title 131
Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor Bright
###end article-title 131
###begin article-title 132
Induction of immunoglobulin heavy chain transcription through the transcription factor Bright requires TFII-I
###end article-title 132
###begin article-title 133
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bright </italic>
Expression of Bright at two distinct stages of B lymphocyte development
###end article-title 133
###begin article-title 134
Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product
###end article-title 134
###begin article-title 135
Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF
###end article-title 135
###begin article-title 136
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
###end article-title 136

